DE2347628C3 - Verfahren zur Gewinnung immunsuppressiver Gammaglobuline und Verwendung der Gammaglobuline zur Behandlung der Implanat-Abstoflung und von Autoaggressionskrankheiten - Google Patents
Verfahren zur Gewinnung immunsuppressiver Gammaglobuline und Verwendung der Gammaglobuline zur Behandlung der Implanat-Abstoflung und von AutoaggressionskrankheitenInfo
- Publication number
- DE2347628C3 DE2347628C3 DE19732347628 DE2347628A DE2347628C3 DE 2347628 C3 DE2347628 C3 DE 2347628C3 DE 19732347628 DE19732347628 DE 19732347628 DE 2347628 A DE2347628 A DE 2347628A DE 2347628 C3 DE2347628 C3 DE 2347628C3
- Authority
- DE
- Germany
- Prior art keywords
- gammagiobulins
- gamma globulins
- immunosuppressive
- treatment
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 8
- 201000010099 disease Diseases 0.000 title claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 6
- 239000007943 implant Substances 0.000 title claims description 5
- 108010074605 gamma-Globulins Proteins 0.000 title description 17
- 238000000605 extraction Methods 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 229940072221 immunoglobulins Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 210000005059 placental tissue Anatomy 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 230000007515 enzymatic degradation Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000001391 lymphocytotoxic effect Effects 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007973 glycine-HCl buffer Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000003293 antilymphocyte serum Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002532 anti-gammaglobulin Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7233703A FR2201078A1 (en) | 1972-09-22 | 1972-09-22 | Gamma globulin immuno depressants - isolated from placental tissue |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2347628A1 DE2347628A1 (de) | 1974-04-04 |
| DE2347628B2 DE2347628B2 (de) | 1980-04-03 |
| DE2347628C3 true DE2347628C3 (de) | 1980-11-27 |
Family
ID=9104675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732347628 Expired DE2347628C3 (de) | 1972-09-22 | 1973-09-21 | Verfahren zur Gewinnung immunsuppressiver Gammaglobuline und Verwendung der Gammaglobuline zur Behandlung der Implanat-Abstoflung und von Autoaggressionskrankheiten |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS577130B2 (enExample) |
| BE (1) | BE805141A (enExample) |
| DE (1) | DE2347628C3 (enExample) |
| FR (1) | FR2201078A1 (enExample) |
| LU (1) | LU68440A1 (enExample) |
| NL (1) | NL175625C (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453255A (fr) * | 1964-12-29 | 1966-06-03 | Procédé d'extraction, notamment d'organes foetaux |
-
1972
- 1972-09-22 FR FR7233703A patent/FR2201078A1/fr active Granted
-
1973
- 1973-09-18 LU LU68440D patent/LU68440A1/xx unknown
- 1973-09-21 BE BE135889A patent/BE805141A/xx not_active IP Right Cessation
- 1973-09-21 NL NL7313080A patent/NL175625C/xx not_active IP Right Cessation
- 1973-09-21 DE DE19732347628 patent/DE2347628C3/de not_active Expired
- 1973-09-22 JP JP10656073A patent/JPS577130B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2201078B1 (enExample) | 1975-10-31 |
| DE2347628A1 (de) | 1974-04-04 |
| BE805141A (fr) | 1974-03-21 |
| DE2347628B2 (de) | 1980-04-03 |
| JPS577130B2 (enExample) | 1982-02-09 |
| NL175625C (nl) | 1984-12-03 |
| NL175625B (nl) | 1984-07-02 |
| JPS4985221A (enExample) | 1974-08-15 |
| FR2201078A1 (en) | 1974-04-26 |
| LU68440A1 (enExample) | 1973-11-26 |
| NL7313080A (enExample) | 1974-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3853923T2 (de) | Kationisierte antikörper für das austragen durch die blut-gehirn-schranke. | |
| DE2606118C2 (de) | Verfahren zur Herstellung eines gereinigten Gamaglobulins und intravenös verabreichbares Arzneimittel | |
| DE2804457C2 (de) | Immunsuppressive Mittel | |
| DE112011102362T5 (de) | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen | |
| EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
| DE112011102409T5 (de) | Verfahren zur Behandlung der Alzheimer-Krankheit | |
| DE1927209A1 (de) | Acyl-substituierte Insuline und Verfahren zu ihrer Herstellung | |
| DE69911322T2 (de) | Monoklonaler antikörper der die oligosaccharide sialinsäure n-glycolierte galactose-glucose auf bösartige tumoren erkennt und zusammensetzungen die dieser enthalten | |
| DE112011102411T5 (de) | Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung | |
| EP0340604B1 (de) | Monoklonaler Antikörper und seine Verwendung | |
| DE69701812T2 (de) | Cyclitol enthaltende kohlenhydrate aus menschlichem gewebe, die die lipogenese-aktivität regulieren | |
| DE3830271A1 (de) | Mittel mit immunsuppressiver wirkung | |
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE69220939T2 (de) | Gegengift immunsera | |
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| DE69434024T2 (de) | Auf humanen cortikalen thymozyten exprimierte oberflächenproteine und ihre verwendung | |
| DE69133166T2 (de) | Inhibitoren von katalytischen antikörpern | |
| DE2347628C3 (de) | Verfahren zur Gewinnung immunsuppressiver Gammaglobuline und Verwendung der Gammaglobuline zur Behandlung der Implanat-Abstoflung und von Autoaggressionskrankheiten | |
| AT395017B (de) | Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates | |
| DE19909357A1 (de) | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt | |
| DE69434256T2 (de) | Immunglobulin-Infusion bei der Xenotransplantation | |
| Roe et al. | Thalidomide and neoplasia | |
| WO1988000836A2 (fr) | Immunosuppresseur et son procede de fabrication | |
| DE2533183C3 (de) | Verfahren zum Herstellen gereinigter Immunglobuline | |
| DE2110436C3 (de) | Verfahren zur Herstellung eines antileukopenischen und antikörperbildenden Thymusextrakts aus Kalbsthymus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: BERENDT, T., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUENCHEN |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: INSTITUT MERIEUX, LYON, RHONE, FR |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: BERENDT, T., DIPL.-CHEM. DR. LEYH, H., DIPL.-ING. DR.-ING. HERING, H., DIPL.-ING., PAT.-ANWAELTE, 8000 MUENCHEN |